
FDA Approves New Treatment for Myasthenia Gravis
WASHINGTON, D.C. — The U.S. Food and Drug Administration recently approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor …
FDA Approves New Treatment for Myasthenia Gravis Read More